The Drug Revolving Fund (DRF) is a sustainable financing mechanism designed to guarantee a constant supply of essential medicines in public health facilities across Nigeria. At its core, the pricing model must ensure that the money generated from selling drugs is enough to buy fresh stock, replacing what was consumed without relying on external government subventions. Unlike commercial pharmacy pricing driven by profit maximization, DRF pricing operates on a no-loss, recovery-based threshold. Understanding this structure helps the nurse manager appreciate why uninterrupted healthcare delivery depends heavily on correct dispensing and accurate accountability at the facility level.
Calculating the final price of a DRF medication requires accounting for several layers of expenditure beyond the basic purchase price from the manufacturer.
Once the total landed cost of a pharmaceutical item is established, a carefully regulated percentage mark-up is applied to determine the patient price. This mark-up is not arbitrary; it is guided by state or institutional policies designed to protect the vulnerable.
$$\text{Retail Price} = \text{Landed Cost} + (\text{Landed Cost} \times \text{Approved Mark-up Percentage})$$
The approved mark-up typically covers internal handling, dispensing materials, and a small buffer for inflation. Facility managers must strictly adhere to these approved percentages to prevent overpricing, which drives patients away from public facilities toward unregulated patent medicine vendors.
A delicate equilibrium must be maintained between keeping drugs cheap for impoverished patients and ensuring the fund does not collapse due to underpricing. If prices are set too low, the revenue collected will fall short of the replacement cost due to currency devaluation and inflation, leading to stock-outs. Conversely, pricing too high defeats the social objective of public healthcare. Nurse leaders and pharmacists participate in drug management committees to review pricing structures regularly, ensuring that the poorest patients retain access while the revolving fund remains solvent over time.
Economic instability and fluctuating exchange rates pose a constant threat to the purchasing power of the DRF. When replacement costs skyrocket overnight, a rigid pricing structure traps the facility in a deficit. To mitigate this, modern DRF guidelines allow for periodic price reviews based on prevailing replacement costs rather than historical purchase prices. Furthermore, maintaining diversified supplier relationships and bulk procurement helps buffer against sudden market shocks, protecting the revolving capital from severe erosion.
Trust is the foundational element that keeps community members utilizing public health facility dispensaries. Transparency in how drug prices are calculated prevents allegations of corruption and extortion among health workers. Regular financial audits, open price lists displayed visibly in the pharmacy, and active oversight by facility health committees ensure that cash collections match the quantity of drugs dispensed. When accountability mechanisms fail, leakages occur, inventory disappears, and the revolving fund collapses despite high patient turnout.